Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa
| Autor: | Suresh Subramaniam, Philip A. Barber, Andrew M. Demchuk, Michael D. Hill, Timothy Watson |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Time Factors Factor VIIa Central nervous system disease Hematoma Posthemorrhagic hydrocephalus medicine Humans cardiovascular diseases Aged Intracerebral hemorrhage biology business.industry Factor VII Middle Aged medicine.disease Recombinant Proteins Clinical trial Recombinant factor VIIa Anesthesia Inclusion and exclusion criteria biology.protein Female Neurology (clinical) Complication business Intracranial Hemorrhages Hydrocephalus |
| Zdroj: | Neurology. 67(6) |
| ISSN: | 1526-632X |
| Popis: | One-third of patients with intracerebral hemorrhage (ICH) are dead within 1 month of symptom onset, and only 20% regain functional independence.1 In a recent Phase IIB study, recombinant Factor VIIa (rFVIIa) given within 4 hours after the onset of ICH significantly reduced hematoma growth and improved clinical outcomes; this effect is being evaluated in a Phase III trial.2 Enthusiasm for the use of rFVIIa is tempered by safety concerns. An increased frequency of thromboembolic complications, notably arterial ischemic events, among patients with ICH treated with rFVIIa has been observed. We report our open-label experience with rFVIIa used within an institution-approved protocol and the occurrence of posthemorrhagic hydrocephalus as an unexpected complication. rFVIIa was administered at a dose of 40 μg/kg body weight to nine patients with ICH diagnosed by CT scan within 3 hours from symptom onset. The inclusion and exclusion criteria for administration of rFVIIa were … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|